Caris Life Sciences (CAI) EBIT Growth (1y) (2025 - 2026)
Powered by 
Analysis
Caris Life Sciences (CAI) EBIT Growth (1y) (2025 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 10.14% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 269.85% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 1,528.74% |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -36.55% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 99.51% |
| 10 | Caris Life Sciences | 7.01 Bn | 6.22 Bn | 182.38 Mn | 249.68% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 249.68% |
| Mar 31, 2026 | 109.11% |
| Dec 31, 2025 | 338.65% |
| Sep 30, 2025 | 153.65% |
| Jun 30, 2025 | 73.16% |